We demonstrated a positive association between NK-cell FcγRIIIa expression at rituximab initiation and EULAR good-to-moderate response at 6-months in RA (n = 18, Mann–Whitney test; p = 0.03; Fig. 5f), but not BILAG MCR in SLE (n = 17, Mann–Whitney test; p = 0.55, Fig. 5g). The gene discussed is FCGR3A; the disease is rheumatoid arthritis.